Spero Therapeutics (NASDAQ:SPRO) Lowered to In-Line Rating by Evercore ISI

Evercore ISI lowered shares of Spero Therapeutics (NASDAQ:SPRO - Free Report) from an outperform rating to an in-line rating in a research report sent to investors on Friday, Marketbeat Ratings reports. They currently have $5.00 target price on the stock.

A number of other research analysts have also weighed in on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $5.00 price target on shares of Spero Therapeutics in a research note on Monday, December 2nd. Cantor Fitzgerald restated an "overweight" rating on shares of Spero Therapeutics in a research report on Friday, November 15th. Finally, TD Cowen reiterated a "hold" rating on shares of Spero Therapeutics in a research report on Monday, November 18th.

Spero Therapeutics Stock Down 4.3 %

Shares of SPRO traded down $0.04 during trading hours on Friday, reaching $0.96. 329,707 shares of the company traded hands, compared to its average volume of 220,100. The business has a fifty day moving average price of $1.20 and a 200-day moving average price of $1.29. Spero Therapeutics has a 12-month low of $0.95 and a 12-month high of $1.89. The stock has a market capitalization of $52.07 million, a P/E ratio of 13.65 and a beta of 0.59.

Hedge Funds Weigh In On Spero Therapeutics

An institutional investor recently raised its position in Spero Therapeutics stock. Acadian Asset Management LLC increased its holdings in Spero Therapeutics, Inc. (NASDAQ:SPRO - Free Report) by 40.6% in the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 1,071,860 shares of the company's stock after acquiring an additional 309,262 shares during the period. Acadian Asset Management LLC owned approximately 1.99% of Spero Therapeutics worth $1,392,000 at the end of the most recent quarter. Institutional investors and hedge funds own 25.60% of the company's stock.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.